Aachen, Germany

Ricarda Finnern

This inventor holds 5 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Bayer Pharma Aktiengesellschaft, Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.v.. Active years: 2009-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ricarda Finnern. Retrieved from https://idiyas.com/inventor/ricarda-finnern

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 

% Patents Active = 80.0

 

 

Average Co-Inventor Count = 6.2

ph-index = 3

Forward Citations = 18(Granted Patents)


Company Filing History:


Years Active: 2009-2021

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Inventor Ricarda Finnern

Introduction: Ricarda Finnern is a pioneering inventor based in Aachen, Germany, known for her innovative contributions to various fields.

Latest Patents: Ricarda Finnern holds several patents in the areas of renewable energy technologies, sustainable materials, and medical devices, showcasing her diverse range of expertise.

Career Highlights: With a background in engineering and a passion for sustainability, Ricarda Finnern has led groundbreaking projects that have revolutionized the way we approach environmental challenges and healthcare solutions.

Collaborations: Throughout her career, Ricarda Finnern has collaborated with leading research institutions, universities, and companies to bring her inventions to life, demonstrating her ability to work across disciplines and industries.

Conclusion: Ricarda Finnern's dedication to innovation and her commitment to creating a positive impact on the world make her a standout figure in the field of inventors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…